If the ultimate goal is to translate sVNS to the clinic to treat obesity, then the technology must compete with well-established bariatric surgical treatments as well as the newer semaglutide GLP-1 and tirzepatide GLP-1/GIP agonists. This evidence concerns the gene GIP and obesity disorder.